蔓越莓A型原花青素选择性靶向急性髓系白血病细胞
研究评估蔓越莓提取物中A型原花青素(A-PAC)对白血病细胞系、原代AML样本及正常CD34+脐血标本的作用,发现其具有强效且特异的体外抗白血病活性,可作用于恶性祖细胞和干细胞群而不伤害正常对应细胞,并在患者来源异种移植模型中观察到体内抗白血病效果,机制由NF-κB激活驱动细胞死亡。
要点
- A-PAC对AML细胞系和原代AML样本显示强效且特异的体外抗白血病活性。
- A-PAC的抗白血病作用扩展至恶性祖细胞和干细胞群,且不伤害正常对应细胞。
- A-PAC在患者来源异种移植模型中显示体内抗白血病效果,机制由NF-κB激活驱动。
核心结论
- A-PAC可能通过靶向白血病干细胞、经由潜在新通路改善AML治疗。
研究设计与样本
- 研究评估从市售蔓越莓提取物中分离的A-PAC对白血病细胞系、原代AML样本和正常CD34+脐血标本的作用,并使用患者来源异种移植模型进行体内验证。
主要发现
- A-PAC在体外显示强效且特异的抗白血病活性。
- A-PAC的抗白血病活性扩展至恶性祖细胞和干细胞群,同时不伤害正常对应细胞。
- 在患者来源异种移植模型中观察到A-PAC的体内抗白血病效果。
- 细胞死亡机制由NF-κB激活驱动。
临床怎么用
- A-PAC有望通过靶向白血病干细胞、经由潜在新通路用于改善AML治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most elderly patients affected with acute myeloid leukemia (AML) will relapse and die of their disease even after achieving complete remission, thus emphasizing the urgent need for new therapeutic approaches with minimum toxicity to normal hematopoietic cells. Cranberry (Vaccinium spp.) extracts have exhibited anticancer and chemopreventive properties that have been mostly attributed to A-type proanthocyanidin (A-PAC) compounds. A-PACs, isolated from a commercially available cranberry extract, were evaluated for their effects on leukemia cell lines, primary AML samples, and normal CD34+ cord blood specimens. Our results indicated potent and specific antileukemia activity in vitro. In addition, the antileukemia activity of A-PACs extended to malignant progenitor and stem cell populations, sparing their normal counterparts. The antileukemia effects of A-PACs were also observed in vivo using patient derived xenografts. Surprisingly, we found that the mechanism of cell death was driven by activation of NF-κB. Overall, our data suggest that A-PACs could be used to improve treatments for AML by targeting leukemia stem cells through a potentially novel pathway.
引用
- Bystrom LM, Bezerra DP, Hsu HT, et al. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood Adv. 2019. PMID: 31698457. doi:10.1182/bloodadvances.2018026633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。